<DOC>
	<DOCNO>NCT00964873</DOCNO>
	<brief_summary>An open-label phase 1 study ass safety efficacy once-weekly STA-9090 ( ganetespib ) subject AML , ALL blast-phase CML .</brief_summary>
	<brief_title>A Phase 1 Study HSP90 Inhibitor , STA-9090 Subjects With Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia Blast-phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<criteria>Subjects pathologic confirmation diagnosis AML , ALL , blastphase CML ECOG Performance Status 02 Adequate organ function define protocol . Ability understand willingness sign write informed consent document . Hyperleukocytosis Acute Promyelocytic Leukemia ( FABM3 ) subtype Uncontrolled Disseminated Intravascular Coagulation ( DIC ) Active central nervous system leukemia Concomitant radiation therapy , chemotherapy , immunotherapy Women pregnant lactate Neuropathy â‰¥ grade 2 ( NCI CTCAE ) time enrollment Chemotherapy ( exception hydroxyurea ) radiotherapy within two week within six time agent 's half life Require ongoing therapy either G GMCSF , longacting version molecule Use investigational agent within two week within six time agent 's half life Treatment chronic immunosuppressant Other medical/psychiatric condition may increase risk associate study participation define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Synta</keyword>
	<keyword>STA-9090</keyword>
	<keyword>ganetespib</keyword>
	<keyword>Hematologic Cancers</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Blast-phase Chronic Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>CML</keyword>
	<keyword>HSP90 Inhibitor</keyword>
</DOC>